Stay updated on Risankizumab Dose Regimens in Japanese GPP/EP Clinical Trial

Sign up to get notified when there's something new on the Risankizumab Dose Regimens in Japanese GPP/EP Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Risankizumab Dose Regimens in Japanese GPP/EP Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    The clinical trial record for the risankizumab study in Japanese participants with generalized pustular or erythrodermic psoriasis is displayed instead of an error page. It includes the study’s design, eligibility criteria, outcome measures, record dates, and participant-data sharing information.
    Difference
    54%
    Check dated 2026-11-07T11:39:43.000Z thumbnail image
  2. Check
    11 days ago
    Change Detected
    Summary
    The footer revision number changed from v3.7.2 to v3.8.0 while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-31T12:22:13.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    A banner was added announcing changes to NIH websites and noting the transition from the term “Artificial Intelligence” to “Super Intelligence.”
    Difference
    1%
    Check dated 2026-10-24T12:33:26.000Z thumbnail image
  4. Check
    25 days ago
    Change Detected
    Summary
    The footer revision changed from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-17T13:34:10.000Z thumbnail image
  5. Check
    32 days ago
    Change Detected
    Summary
    The footer's site revision identifier was updated from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-10T13:30:57.000Z thumbnail image
  6. Check
    46 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error instead of the expected study page content. The access-restricted error is shown while the site chrome (header/footer) remains visible, indicating the study record is not accessible at this time.
    Difference
    0.5%
    Check dated 2026-09-26T17:11:40.000Z thumbnail image

Stay in the know with updates to Risankizumab Dose Regimens in Japanese GPP/EP Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Risankizumab Dose Regimens in Japanese GPP/EP Clinical Trial page.